UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued:
15 April 2026, London UK
GSK completes acquisition of 35Pharma
Inc.
GSK plc
(LSE/NYSE: GSK) today announced the completion of
its acquisition of
35Pharma Inc., a Canada-based, private, clinical-stage
biopharmaceutical company specialising in the development of novel
protein-based therapeutics. The acquisition includes HS235, a
potential best-in-class molecule for the treatment of pulmonary
hypertension (PH). HS235 targets the activin receptor signalling
pathway, a clinically validated therapeutic target in PH. The
global market for PH therapies is forecast to reach $18 billion by
2032, with activin signalling inhibitors expected to account for
50% of this.1
HS235
is designed with enhanced selectivity providing the potential to
lower the risk of bleeding, pericardial effusion and dose-limiting
increases in haemoglobin, addressing key limitations in current
pulmonary arterial hypertension (PAH) treatment. The underlying
mechanism of HS235 also offers the potential for broad metabolic
benefits, as observed in early clinical studies, including
fat-selective weight loss, preservation of lean mass, and improved
insulin sensitivity. If confirmed in future clinical trials, this
could bring additional clinical and commercial value given the high
prevalence of obesity and insulin resistance in the broader PH
population.
Kaivan Khavandi, SVP, R&D Head Respiratory, Immunology &
Inflammation (RI&I), and Head of Translational &
Development Sciences, GSK, said: "HS235 is an important
addition to our RI&I pipeline, which continues to expand across
inflammatory and fibrotic drivers underlying multiple chronic
diseases. With approximately 82 million patients currently living
with PH in its various forms, high burden of morbidity associated
with the disease and poor associated prognosis, with low five-year
survival rates, we are committed to advancing this novel,
differentiated option to expand the limited treatments currently
available."
HS235
complements GSK's current RI&I portfolio, adding to a pipeline
already targeting the inflammatory and fibrotic drivers of chronic
disease. It also builds on a growing set of mechanisms that can
expand across the metabolic and vascular components of lung, liver
and kidney disease. Proof-of-concept trials are expected to start
imminently in two forms of PH: PAH and pulmonary hypertension due
to heart failure with preserved ejection fraction
(PH-HFpEF).
Financial considerations
Under
the terms of the agreement, GSK has acquired 100% of the equity of
35Pharma Inc. for $950 million.
About pulmonary hypertension (PH)
Pulmonary
hypertension (PH) is a progressive, life-shortening disease marked
by high blood pressure in the lungs. There are different types of
PH such as pulmonary arterial hypertension (PAH) and PH due to
heart failure with preserved ejection fraction (PH-HFpEF). PH
affects approximately 82 million people worldwide across multiple
disease forms, yet treatment options remain limited and the
five-year survival rate is only around 50%.2.3 PH is managed
by a concentrated base of pulmonologists and cardiologists, with
patients often treated at PH centres.
About HS235
HS235
targets the activin receptor signalling pathway, a clinically
validated therapeutic target in PH. HS235 is designed with enhanced
selectivity, reducing binding to BMP9 and BMP10 - ligands
associated with adverse events such as bleeding and telangiectasia
(broken blood vessels). By potentially lowering the risk of
bleeding, HS235 may address a key limitation in current PH
treatment, particularly as a significant proportion of patients
require concomitant anticoagulant or antiplatelet
therapy.
About GSK
GSK is
a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Sydney
Dodson-Nease
|
+1 215
370 4680
|
(Philadelphia)
|
|
|
|
|
|
|
Investor
Relations:
|
Constantin
Fest
|
+44 (0)
7831 826525
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Sam
Piper
|
+44 (0)
7824 525779
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for
2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79 New
Oxford Street
London
WC1A
1DG
References
1.
Evaluate Pharma consensus estimate; accessed Feb 2026.
2.
Humbert, M. et al. (2022) 2022 ESC/ERS Guidelines for the diagnosis
and treatment of pulmonary hypertension, European Heart Journal,
43(38), pp. 3618-3731. doi:10.1093/eurheartj/ehac237.
3.
Caravita S, Faini A, D'Araujo SC, et al. Clinical phenotypes and
outcomes of pulmonary hypertension due to left heart disease: Role
of the pre-capillary component. PLOS ONE. 2018;13(6):e0199164.
doi:10.1371/journal.pone.0199164.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
15, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|